BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueo H, Sugimachi K, Gorges TM, Bartkowiak K, Yokobori T, Müller V, Shinden Y, Ueda M, Ueo H, Mori M, Kuwano H, Maehara Y, Ohno S, Pantel K, Mimori K. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br J Cancer 2015;112:1519-26. [PMID: 25880010 DOI: 10.1038/bjc.2015.132] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Alvarez Cubero MJ, Lorente JA, Robles-fernandez I, Rodriguez-martinez A, Puche JL, Serrano MJ. Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection. In: M. Magbanua MJ, W. Park J, editors. Circulating Tumor Cells. New York: Springer; 2017. pp. 283-303. [DOI: 10.1007/978-1-4939-7144-2_24] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
2 Xin Z, Li D, Mao F, Du Y, Wang X, Xu P, Li Z, Qian J, Yao J. PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling. J Cell Physiol 2020;235:8416-23. [PMID: 32239705 DOI: 10.1002/jcp.29685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lu YJ, Wang P, Wang X, Peng J, Zhu YW, Shen N. The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis. Oncotarget. 2016;7:37361-37369. [PMID: 27008698 DOI: 10.18632/oncotarget.8156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
4 Lianidou ES. Gene expression profiling and DNA methylation analyses of CTCs. Mol Oncol 2016;10:431-42. [PMID: 26880168 DOI: 10.1016/j.molonc.2016.01.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
5 Kowalik A, Kowalewska M, Góźdź S. Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. Transl Res 2017;185:58-84.e15. [PMID: 28506696 DOI: 10.1016/j.trsl.2017.04.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 13.6] [Reference Citation Analysis]
6 Yadavalli S, Jayaram S, Manda SS, Madugundu AK, Nayakanti DS, Tan TZ, Bhat R, Rangarajan A, Chatterjee A, Gowda H, Thiery JP, Kumar P. Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells. Sci Rep. 2017;7:43710. [PMID: 28262832 DOI: 10.1038/srep43710] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
7 Burinaru TA, Avram M, Avram A, Mărculescu C, Ţîncu B, Ţucureanu V, Matei A, Militaru M. Detection of Circulating Tumor Cells Using Microfluidics. ACS Comb Sci 2018;20:107-26. [PMID: 29363937 DOI: 10.1021/acscombsci.7b00146] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
8 Markiewicz A, Topa J, Nagel A, Skokowski J, Seroczynska B, Stokowy T, Welnicka-Jaskiewicz M, Zaczek AJ. Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. Cancers (Basel) 2019;11:E59. [PMID: 30634453 DOI: 10.3390/cancers11010059] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
9 Xiong F, Wu GH, Wang B, Chen YJ. Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma. Cancer Cell Int 2021;21:411. [PMID: 34348730 DOI: 10.1186/s12935-021-02117-1] [Reference Citation Analysis]
10 Burr R, Gilles C, Thompson EW, Maheswaran S. Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis. Adv Exp Med Biol 2020;1220:11-34. [PMID: 32304077 DOI: 10.1007/978-3-030-35805-1_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci Rep 2016;6:39736. [PMID: 28000772 DOI: 10.1038/srep39736] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
12 Freudenmann LK, Mayer C, Rodemann HP, Dittmann K. Reduced exosomal L-Plastin is responsible for radiation-induced bystander effect. Exp Cell Res 2019;383:111498. [PMID: 31302031 DOI: 10.1016/j.yexcr.2019.111498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Song W, Mazzieri R, Yang T, Gobe GC. Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition. Front Immunol 2017;8:1106. [PMID: 28955335 DOI: 10.3389/fimmu.2017.01106] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
14 Ma Y, Lai W, Zhao M, Yue C, Shi F, Li R, Hu Z. Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway. Artif Cells Nanomed Biotechnol 2019;47:685-95. [PMID: 30829071 DOI: 10.1080/21691401.2019.1576707] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
15 Shi F, Ma Y, Qian Y, Wang Y, Wang Z, Zhao M, Hu Z. A Novel Peptide Probe for Identification of PLS3-Expressed Cancer Cells. Anal Chem 2019;91:9640-7. [PMID: 31293151 DOI: 10.1021/acs.analchem.9b01061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lapin M, Tjensvoll K, Oltedal S, Javle M, Smaaland R, Gilje B, Nordgård O. Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. BMC Cancer 2017;17:390. [PMID: 28569190 DOI: 10.1186/s12885-017-3385-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
17 Lampignano R, Schneck H, Neumann M, Fehm T, Neubauer H. Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells. Adv Exp Med Biol 2017;994:181-203. [PMID: 28560675 DOI: 10.1007/978-3-319-55947-6_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
18 Alix-panabières C, Mader S, Pantel K. Epithelial-mesenchymal plasticity in circulating tumor cells. J Mol Med 2017;95:133-42. [DOI: 10.1007/s00109-016-1500-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 11.8] [Reference Citation Analysis]
19 Gorges TM, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse SA, Pantel K. Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®. PLoS One 2016;11:e0155126. [PMID: 27182774 DOI: 10.1371/journal.pone.0155126] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
20 Belthier G, Homayed Z, Grillet F, Duperray C, Vendrell J, Krol I, Bravo S, Boyer JC, Villeronce O, Vitre-Boubaker J, Heaug-Wane D, Macari-Fine F, Smith J, Merlot M, Lossaint G, Mazard T, Portales F, Solassol J, Ychou M, Aceto N, Mamessier E, Bertucci F, Pascussi JM, Samalin E, Hollande F, Pannequin J. CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers (Basel) 2021;13:4966. [PMID: 34638450 DOI: 10.3390/cancers13194966] [Reference Citation Analysis]
21 de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D. Urothelial cancer proteomics provides both prognostic and functional information. Sci Rep 2017;7:15819. [PMID: 29150671 DOI: 10.1038/s41598-017-15920-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
22 Wolff L, Strathmann EA, Müller I, Mählich D, Veltman C, Niehoff A, Wirth B. Plastin 3 in health and disease: a matter of balance. Cell Mol Life Sci 2021;78:5275-301. [PMID: 34023917 DOI: 10.1007/s00018-021-03843-5] [Reference Citation Analysis]
23 Lampignano R, Yang L, Neumann MHD, Franken A, Fehm T, Niederacher D, Neubauer H. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. Int J Mol Sci 2017;18:E1885. [PMID: 28858218 DOI: 10.3390/ijms18091885] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
24 Zhang ZP, Zhang XF, Li H, Liu TJ, Zhao QP, Huang LH, Cao ZJ, He LM, Hao DJ. Serum irisin associates with breast cancer to spinal metastasis. Medicine (Baltimore) 2018;97:e0524. [PMID: 29703023 DOI: 10.1097/MD.0000000000010524] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
25 Moerman-Herzog A, Mehdi SJ, Wong HK. Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome. Cells 2020;9:E1992. [PMID: 32872487 DOI: 10.3390/cells9091992] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol. 2016;10:408-417. [PMID: 26899533 DOI: 10.1016/j.molonc.2016.01.010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
27 Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabariès S, Gettemans J, Siegel PM, Komarova SV. Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. Transl Oncol 2019;12:462-74. [PMID: 30583289 DOI: 10.1016/j.tranon.2018.11.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
28 Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Per Med 2016;13:469-84. [PMID: 29767597 DOI: 10.2217/pme-2016-0020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
29 Velthaus A, Cornils K, Hennigs JK, Grüb S, Stamm H, Wicklein D, Bokemeyer C, Heuser M, Windhorst S, Fiedler W, Wellbrock J. The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. Cancers (Basel) 2019;11:E1663. [PMID: 31717802 DOI: 10.3390/cancers11111663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kuriyama K, Yokobori T, Sohda M, Nakazawa N, Yajima T, Naruse I, Kuwano H, Shirabe K, Kaira K, Saeki H. Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab. Oncol Lett 2021;21:11. [PMID: 33240417 DOI: 10.3892/ol.2020.12272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Sun NY, Yang MH. Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy. Front Oncol 2020;10:792. [PMID: 32509584 DOI: 10.3389/fonc.2020.00792] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
32 Masuda T, Ueo H, Kai Y, Noda M, Hu Q, Sato K, Fujii A, Hayashi N, Tsuruda Y, Otsu H, Kuroda Y, Eguchi H, Ohno S, Mimori K, Ueo H. N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study. Int J Mol Sci 2020;21:E511. [PMID: 31947504 DOI: 10.3390/ijms21020511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Lapin M, Tjensvoll K, Oltedal S, Buhl T, Gilje B, Smaaland R, Nordgård O. MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment. Sci Rep 2016;6:28929. [PMID: 27432216 DOI: 10.1038/srep28929] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
34 Topa J, Grešner P, Żaczek AJ, Markiewicz A. Breast cancer circulating tumor cells with mesenchymal features-an unreachable target? Cell Mol Life Sci 2022;79:81. [PMID: 35048186 DOI: 10.1007/s00018-021-04064-6] [Reference Citation Analysis]
35 Hu Q, Masuda T, Koike K, Sato K, Tobo T, Kuramitsu S, Kitagawa A, Fujii A, Noda M, Tsuruda Y, Otsu H, Kuroda Y, Ito S, Oki E, Mimori K. Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. Sci Rep 2021;11:19178. [PMID: 34584127 DOI: 10.1038/s41598-021-98485-9] [Reference Citation Analysis]
36 Li X, Sun H, Liu Q, Liu Y, Hou Y, Jin W. A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy. Cancer Med 2021;10:4658-74. [PMID: 34076352 DOI: 10.1002/cam4.4022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. Gene 2017;596:137-46. [PMID: 27760381 DOI: 10.1016/j.gene.2016.10.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
38 Khassan O, Jensen KV, Woodman AG, Vogel HJ, Ishida H. Characterization of the EF-Hand Calcium-Binding Domains of Human Plastins. Methods Mol Biol 2019;1929:245-60. [PMID: 30710278 DOI: 10.1007/978-1-4939-9030-6_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2017;28:468-477. [PMID: 27998963 DOI: 10.1093/annonc/mdw619] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
40 Alix-Panabières C, Bartkowiak K, Pantel K. Functional studies on circulating and disseminated tumor cells in carcinoma patients. Mol Oncol 2016;10:443-9. [PMID: 26847851 DOI: 10.1016/j.molonc.2016.01.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]